(firstQuint)Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects.

 This is a double-blind, randomized, placebo-controlled, dose-escalating study.

 The study comprises single dose (Stage I) and multiple dose (Stage II) stages.

 Stage II will not be initiated until completion of Stage I.

 The interim safety analysis report will be submitted to TFDA for an approval for proceeding to Stage II.

.

 Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects@highlight

This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and multiple dose study.

